Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

Longitudinal study of antibody reactivity against HIV-1 envelope and a peptide representing a conserved site on Gp41 in HIV-1-infected patients.

Mühlbacher M, Spruth M, Siegel F, Zangerle R, Dierich MP.

Immunobiology. 1999 Jun;200(2):295-305.

PMID:
10416136
2.

Envelope sequence variability and serologic characterization of HIV type 1 group O isolates from equatorial guinea.

Hunt JC, Golden AM, Lund JK, Gürtler LG, Zekeng L, Obiang J, Kaptué L, Hampl H, Vallari A, Devare SG.

AIDS Res Hum Retroviruses. 1997 Aug 10;13(12):995-1005.

PMID:
9264286
3.

Viremic HIV infected individuals with high CD4 T cells and functional envelope proteins show anti-gp41 antibodies with unique specificity and function.

Curriu M, Fausther-Bovendo H, Pernas M, Massanella M, Carrillo J, Cabrera C, López-Galíndez C, Clotet B, Debré P, Vieillard V, Blanco J.

PLoS One. 2012;7(2):e30330. doi: 10.1371/journal.pone.0030330. Epub 2012 Feb 1.

4.

Association of antibody reactivity to ELDKWA, a glycoprotein 41 neutralization epitope, with disease progression in children perinatally infected with HIV type 1.

Geffin RB, Scott GB, Melenwick M, Hutto C, Lai S, Boots LJ, McKenna PM, Kessler JA 2nd, Conley AJ.

AIDS Res Hum Retroviruses. 1998 May 1;14(7):579-90.

PMID:
9591712
5.
6.

Humoral response to oligomeric human immunodeficiency virus type 1 envelope protein.

Richardson TM Jr, Stryjewski BL, Broder CC, Hoxie JA, Mascola JR, Earl PL, Doms RW.

J Virol. 1996 Feb;70(2):753-62.

7.

Direct antibody access to the HIV-1 membrane-proximal external region positively correlates with neutralization sensitivity.

Chakrabarti BK, Walker LM, Guenaga JF, Ghobbeh A, Poignard P, Burton DR, Wyatt RT.

J Virol. 2011 Aug;85(16):8217-26. doi: 10.1128/JVI.00756-11. Epub 2011 Jun 8.

8.

Co-receptor Binding Site Antibodies Enable CD4-Mimetics to Expose Conserved Anti-cluster A ADCC Epitopes on HIV-1 Envelope Glycoproteins.

Richard J, Pacheco B, Gohain N, Veillette M, Ding S, Alsahafi N, Tolbert WD, Prévost J, Chapleau JP, Coutu M, Jia M, Brassard N, Park J, Courter JR, Melillo B, Martin L, Tremblay C, Hahn BH, Kaufmann DE, Wu X, Smith AB 3rd, Sodroski J, Pazgier M, Finzi A.

EBioMedicine. 2016 Oct;12:208-218. doi: 10.1016/j.ebiom.2016.09.004. Epub 2016 Sep 9.

9.

Complement-mediated enhancement of HIV-1 neutralisation by anti-HLA antibodies derived from polytransfused patients.

Wilfingseder D, Spruth M, Ammann CG, Döpper S, Speth C, Dierich MP, Stoiber H.

Int Arch Allergy Immunol. 2003 May;131(1):62-72.

PMID:
12759492
10.

Heterologous epitope-scaffold prime:boosting immuno-focuses B cell responses to the HIV-1 gp41 2F5 neutralization determinant.

Guenaga J, Dosenovic P, Ofek G, Baker D, Schief WR, Kwong PD, Karlsson Hedestam GB, Wyatt RT.

PLoS One. 2011 Jan 26;6(1):e16074. doi: 10.1371/journal.pone.0016074.

11.

The V3-directed immune response in natural human immunodeficiency virus type 1 infection is predominantly directed against a variable, discontinuous epitope presented by the gp120 V3 domain.

Schreiber M, Wachsmuth C, Müller H, Odemuyiwa S, Schmitz H, Meyer S, Meyer B, Schneider-Mergener J.

J Virol. 1997 Dec;71(12):9198-205.

12.

Functional characterization of two scFv-Fc antibodies from an HIV controller selected on soluble HIV-1 Env complexes: a neutralizing V3- and a trimer-specific gp41 antibody.

Trott M, Weiβ S, Antoni S, Koch J, von Briesen H, Hust M, Dietrich U.

PLoS One. 2014 May 14;9(5):e97478. doi: 10.1371/journal.pone.0097478. eCollection 2014. Erratum in: PLoS One. 2014;9(8):e107089.

14.

Changes in HIV-specific antibody responses and neutralization titers in patients under ART.

Falkensammer B, Freissmuth D, Hübner L, Speth C, Dierich MP, Stoiber H.

Front Biosci. 2007 Jan 1;12:2148-58.

PMID:
17127452
15.

Immunogenic presentation of a conserved gp41 epitope of human immunodeficiency virus type 1 on recombinant surface antigen of hepatitis B virus.

Eckhart L, Raffelsberger W, Ferko B, Klima A, Purtscher M, Katinger H, Rüker F.

J Gen Virol. 1996 Sep;77 ( Pt 9):2001-8.

PMID:
8810996
16.

Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infection.

Alam SM, Scearce RM, Parks RJ, Plonk K, Plonk SG, Sutherland LL, Gorny MK, Zolla-Pazner S, Vanleeuwen S, Moody MA, Xia SM, Montefiori DC, Tomaras GD, Weinhold KJ, Karim SA, Hicks CB, Liao HX, Robinson J, Shaw GM, Haynes BF.

J Virol. 2008 Jan;82(1):115-25. Epub 2007 Oct 17.

17.

Selection of human anti-human immunodeficiency virus type 1 envelope single-chain antibodies from a peripheral blood cell-based phage repertoire.

de Haard JJ, Kazemier B, Oudshoorn P, Boender P, van Gemen B, Koolen MJ, van der Groen G, Hoogenboom HR, Arends JW.

J Gen Virol. 1998 Dec;79 ( Pt 12):2883-94.

PMID:
9880001
19.

A synthetic peptide from the first conserved region in the envelope protein gp160 is a strong T-cell epitope in HIV-infected chimpanzees and humans.

Nehete PN, Schapiro SJ, Johnson PC, Murthy KK, Satterfield WC, Sastry KJ.

Viral Immunol. 1998;11(3):147-58.

PMID:
9918406
20.

HIV type 1 Env precursor cleavage state affects recognition by both neutralizing and nonneutralizing gp41 antibodies.

Chakrabarti BK, Pancera M, Phogat S, O'Dell S, McKee K, Guenaga J, Robinson J, Mascola J, Wyatt RT.

AIDS Res Hum Retroviruses. 2011 Aug;27(8):877-87. doi: 10.1089/AID.2010.0281. Epub 2011 Jan 19.

Supplemental Content

Support Center